Inflammation and Neuroaxonal Injury in Multiple Sclerosis and AIDS Dementia Complex: Implications for Neuroprotective Treatment

 

 Buy Article Permissions and Reprints

Abstract

Multiple sclerosis (MS) and AIDS dementia complex (ADC), also termed HIV-associated dementia (HAD), are two examples of CNS diseases with a strong inflammatory component. In particular, macrophage/microglia activation in the deep white matter (DWM) is a key feature of both diseases. Activated macrophages/microglia have been shown to produce multiple cellular substances which can cause injury and apoptosis to all cell types in the CNS. This potentially provides a link between the initial pathogenic event and subsequent widespread neuroaxonal injury, which recent studies have found to be an early finding and an important determinant of clinical burden in both diseases. This review summarizes important immunopathological and neurobiological aspects of MS and ADC, with a special focus on the relation between macrophage/microglia activation and neuroaxonal injury, and discusses potential neuroprotective strategies.

References

• 1 De Simone R, Giampaolo A, Giometto B, Gallo P, Levi G, Peschle C, Aloisi F. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions.  J Neuropathol Exp Neurol. 1995;  54 175-187
  PubMedGoogle Scholar
• 2 Panek R B, Benveniste E N. Class II MHC gene expression in microglia. Regulation by the cytokines IFN-gamma, TNF-alpha, and TGF-beta.  J Immunol. 1995;  154 2846-2854
  PubMedGoogle Scholar
• 3 Wilt S G, Milward E, Zhou J M, Nagasato K, Patton H, Rusten R, Griffin D E, O'Connor M, Dubois-Dalcq M. In vitro evidence for a dual role of tumor necrosis factor alpha in human immunodeficiency virus type 1 encephalopathy.  Ann Neurol. 1995;  37 381-394
  CrossrefPubMedGoogle Scholar
• 4 Yeung M C, Pulliam L, Lau A S. The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor.  AIDS. 1995;  9 137-143
  PubMedGoogle Scholar
• 5 Adamson D C, Wildemann B, Sasaki M, Glass J D, McArthur J C, Christov V I, Dawson T M, Dawson V L. Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp 41.  Science. 1996;  274 1917-1920
  CrossrefPubMedGoogle Scholar
• 6 Kaul M, Lipton S. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis.  Proc Natl Acad Sci USA. 1999;  96 8212-8216
  CrossrefPubMedGoogle Scholar
• 7 Rostásy K M, Monti L, Yiannoutsos C, Kneissl M, Bell J, Kemper T L. et al . HIV infection, iNOS expression and microglial activation: pathogenetic relationship to the AIDS dementia complex.  Ann Neurol. 1999;  46 207-216
  CrossrefPubMedGoogle Scholar
• 8 Werner P, Pitt D, Raine C S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocytes and axonal damage.  Ann Neurol. 2001;  50 169-180
  CrossrefPubMedGoogle Scholar
• 9 Masliah E, Heaton R K, Marcotte T D, Ellie R J, Wiley C A, Mallory M. et al . Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC group. HIV Neurobehavioural Research Center.  Ann Neurol. 1997;  42 963-972
  CrossrefPubMedGoogle Scholar
• 10 Everall I P, Heaton R K, Marcotte T D, Ellis R J, McCutchan J A, Atkinson J H. et al . Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus cognitive disorder. HNRC group. HIV Neurobehavioural Research Center.  Brain Pathol. 1999;  9 209-217
  PubMedGoogle Scholar
• 11 Trapp B D, Jeterson J, Ransohoff R M, Rudick R, Moerk S, Boe L. Axonal transection in the lesions of multiple sclerosis.  N Engl J Med. 1998;  338 278-285
  CrossrefPubMedGoogle Scholar
• 12 Trapp B D, Ransohoff R M, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability.  Curr Opin Neurol. 1999;  12 295-302
  CrossrefPubMedGoogle Scholar
• 13 Pelletier J, Suchet L, Witjas T, Habib M, Guttmann C R, Salamon G. et al . A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis.  Arch Neurol. 2001;  58 105-111
  CrossrefPubMedGoogle Scholar
• 14 Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brueck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decrease over time.  Brain. 2002;  125 2202-2212
  CrossrefPubMedGoogle Scholar
• 15 Adle-Biassette H, Chretien F, Wingertsmann L, Hery C, Ereau T, Scaravelli F, Tardieu M, Gray F. Neuronal apoptosis does not correlate with dementia in HIV-infection but is related to microglial activation and axonal damage.  Neuropathol Appl Neurobiol. 1999;  25 123-133
  CrossrefPubMedGoogle Scholar
• 16 Pesini P, Kopp J, Wong H, Walsh J H, Grant G, Hokfelt T. An immunohistochemical marker for Wallerian degeneration of fibers in the central and peripheral nervous system.  Brain Res. 1999;  828 41-59
  CrossrefPubMedGoogle Scholar
• 17 Mathews P M, De Stefano N, Narayanan S, Francis G S, Wolinsky J S, Antel J P. et al . Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis.  Semin Neurol. 1998;  18 327-336
  PubMedGoogle Scholar
• 18 De Stefano N, Matthews P M, Fu L, Narayanan S, Stanley J, Francis G S, Antel J P, Arnold D L. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.  Brain. 1998;  121 1469-1477
  CrossrefPubMedGoogle Scholar
• 19 Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex.  Neurology. 1999;  52 100-108
  CrossrefPubMedGoogle Scholar
• 20 Yiannoutsos C T, Ernst T, Chang L, Lee P L, Richards T, Marra C M. et al . Regional patterns of brain metabolites in AIDS dementia complex.  NeuroImage. 2004;  23 928-935
  CrossrefPubMedGoogle Scholar
• 21 Chang L, Lee P L, Yiannoutsos C, Ernst T, Marra C, Richards T. et al . A multicenter in vivo proton MRS study of HIV-associated brain injury and the effects of aging.  NeuroImage. 2004;  23 1336-1347
  CrossrefPubMedGoogle Scholar
• 22 Kapaki E, Paraskevas G P, Michalopoulou M, Kilidieas K. Increased cerebrospinal fluid tau protein in multiple sclerosis.  Eur Neurol. 2000;  43 228-232
  CrossrefPubMedGoogle Scholar
• 23 Süssmuth S D, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases.  Neurosci Lett. 2001;  300 95-98
  CrossrefPubMedGoogle Scholar
• 24 Rostásy K M, Withut E, Pohl D, Lange P, Ciesielcyk B, Diehm R, Gärtner J, Otto M. Tau, phospho-tau and S-100 B protein in cerebrospinal fluid of children with multiple sclerosis.  J Child Neurol. 2005;  in press
  PubMedGoogle Scholar
• 25 Duquette P, Murray T J, Pleines J, Ebers G C, Sadovnick D, Weldon P. et al . Multiple sclerosis in childhood: clinical profile in 125 patients.  J Pediatr. 1987;  111 359-363
  CrossrefPubMedGoogle Scholar
• 26 Simone I L, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F. et al . Course and prognosis in early-onset MS. Comparison with adult-onset forms.  Neurology. 2002;  59 1922-1928
  CrossrefPubMedGoogle Scholar
• 27 Hohol M J, Olek M J, Orav E J, Stazzone L, Hafler D A, Khoury S J. et al . Treatment of progressive multiple sclerosis with pulse cyclophosphomide/methylprednisolone: response to therapy is linked to the duration of progressive disease.  Mult Scler. 1999;  5 403-409
  CrossrefPubMedGoogle Scholar
• 28 Amato M P, Ponziani G, Bartolozzi M L, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials.  J Neurol Sci. 1999;  168 96-106
  CrossrefPubMedGoogle Scholar
• 29 Noseworthy J H, Lucchinetti C, Rodriguez M, Weinshenker B G. Multiple sclerosis.  N Engl J Med. 2000;  343 938-952
  CrossrefPubMedGoogle Scholar
• 30 Filippi M. Magnetic resonance imaging findings predicting subsequent disease course in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis.  Neurol Sci. 2001;  22 (Suppl 2) S49-51
  CrossrefPubMedGoogle Scholar
• 31 Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.  Ann Neurol. 2000;  47 707-717
  CrossrefPubMedGoogle Scholar
• 32 Bitch A, Schuchaerdt, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation.  Brain. 2000;  123 1174-1783
  CrossrefPubMedGoogle Scholar
• 33 Peterson J W, Bo L, Mork S, Chang A, Trapp B D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.  Ann Neurol. 2001;  50 389-400
  CrossrefPubMedGoogle Scholar
• 34 Hanefeld F, Bauer H J, Christen H J, Kruse B, Bruhn H, Frahm J. Multiple sclerosis in childhood: report of 15 cases.  Brain Dev. 1991;  13 410-416
  PubMedGoogle Scholar
• 35 Paolillo A, Pozzilli C, Gasperini C, Giugni E, Mainero C, Giuliani S. et al . Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability.  J Neurol Sci. 2000;  174 85-91
  CrossrefPubMedGoogle Scholar
• 36 Barkhof F. Assessing treatment effects on axonal loss-evidence from MRI monitored clinical trials.  J Neurol. 2004;  251 (Suppl 4) IV6-12
  PubMedGoogle Scholar
• 37 Smith K J, Kapoor R, Felts P A. Demyelination: the role of reactive oxygen and nitrogen species.  Brain Pathol. 1999;  9 69-92
  PubMedGoogle Scholar
• 38 Smith K J, Kapoor R, Hall S M, Davies M. Electrically active axons degenerate when exposed to nitric oxide.  Ann Neurol. 2001;  49 470-476
  CrossrefPubMedGoogle Scholar
• 39 Kapoor R, Davies M, Baker P, Hall S M, Smith K J. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration.  Ann Neurol. 2003;  53 74-83
  PubMedGoogle Scholar
• 40 Werner P, Pitt D, Raine C S. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage.  Ann Neurol. 2001;  50 169-180
  CrossrefPubMedGoogle Scholar
• 41 Edgar J M, McLaughlin M, Yool D, Zhang S C, Fowler J H, Montague P. et al . Oligodendroglial modulation of fast axonal transport in a mouse model of hereditary spastic paraplegia.  Cell Biol. 2004;  166 121-131
  PubMedGoogle Scholar
• 42 Diestel A, Aktas O, Hackel D, Häke I, Neier S, Raine C S. et al . Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage.  J Exp Med. 2004;  198 1729-1740
  PubMedGoogle Scholar
• 43 Gveric D, Kaltschmidt C, Cuzner L, Newcombe J. Transcription factor NF-κB and inhibitor IkBa are localized in macrophages in active Multiple Sclerosis lesions.  J Neuropath Exp Neurol. 1998;  57 168-178
  PubMedGoogle Scholar
• 44 Rostásy K M, Monti L, Yiannoutsos C, Wu J, Bell J, Hedreen J, Navia B A. NFkB activation, TNF-α expression, and apoptosis in the AIDS-dementia-complex.  J NeuroVirol. 2000;  6 537-543
  PubMedGoogle Scholar
• 45 Craner M J, Hains B C, Lo A C, Black J A, Waxman S G. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE.  Brain. 2004;  127 294-303
  CrossrefPubMedGoogle Scholar
• 46 Craner M J, Newcombe J, Black J A, Hartle C, Cuzner M L, Waxman S G. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na⁺/Ca²⁺ exchanger.  Proc Natl Acad Sci USA. 2004;  101 8168-8173
  CrossrefPubMedGoogle Scholar
• 47 Stys P K, Waxman S G, Ransom B R. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na⁺ channels and Na(⁺)-Ca²⁺ exchanger.  J Neurosci. 1992;  12 430-439
  PubMedGoogle Scholar
• 48 Shields D C, Schaecher K E, Saido T C, Banik N L. A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain.  Proc Natl Acad Sci USA. 1999;  96 11486-11491
  CrossrefPubMedGoogle Scholar
• 49 Silber E, Semra Y K, Gregson N A, Sharief M K. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.  Neurology. 2002;  58 1372-1381
  CrossrefPubMedGoogle Scholar
• 50 Pender M P. The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair?.  J Clin Neurosci. 2004;  11 689-692
  CrossrefPubMedGoogle Scholar
• 51 Yong V W. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.  Neurology. 2002;  59 802-808
  CrossrefPubMedGoogle Scholar
• 52 Calabresi P A, Pelfrey C M, Tranquill L R, Maloni H, McFarland H F. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta.  Neurology. 1997;  49 1111-1116
  PubMedGoogle Scholar
• 53 Schreiner B, Mitsdoerffer M, Kieseier B C, Chen L, Hartung H P, We M, Wiendl H. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.  J Neuroimmunol. 2004;  155 172-182
  CrossrefPubMedGoogle Scholar
• 54 Avolio C, Giuliani F, Liuzzi G M, Ruggieri M, Paolicelli D, Riccio P. et al . Adhesion molecules and matrix metalloproteinases in multiple sclerosis: effects induced by interferon-beta.  Brain Res Bull. 2003;  61 357-364
  CrossrefPubMedGoogle Scholar
• 55 Duda P W, Schmied M C, Cook S L, Krieger J I, Hafler D A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.  J Clin Invest. 2000;  105 967-976
  PubMedGoogle Scholar
• 56 PRISMS study group . Randomized double-blind placebo-controlled study of interferon-1 a in relapsing/remitting multiple sclerosis.  Lancet. 1998;  352 1498-1504
  CrossrefPubMedGoogle Scholar
• 57 PRISMSMS/MRI study group and the University of British Columbia Analysis Group . PRISMS-4: Long-term efficacy of interferon-1 a in relapsing MS.  Neurology. 2001;  56 1628-1636
  PubMedGoogle Scholar
• 58 Johnson K P, Brooks B R, Cohen J A, Ford C C, Goldstein J, Lisak R P. et al . Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial.  Neurology. 2001;  57 S16-24
  PubMedGoogle Scholar
• 59 Pohl P, Rostásy K M, Gärtner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon-beta-1 a.  Neurology. 2005;  64 888-890
  CrossrefPubMedGoogle Scholar
• 60 Miller D H, Khan O A, Sheremata W A, Blumhardt L D, Rice G P, Libonati M A. et al . International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing- remitting multiple sclerosis.  N Engl J Med. 2003;  348 15-23
  CrossrefPubMedGoogle Scholar
• 61 Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator.  Nat Med. 2000;  6 1399-1402
  CrossrefPubMedGoogle Scholar
• 62 Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier B C, Niederwieser G, Hartung H P, Archelos J J. Statins as immunomodulators: comparison with interferon-beta 1 b in MS.  Neurology. 2000;  59 990-997
  PubMedGoogle Scholar
• 63 Prieto J M, Dapena D, Lema M, Ares B, Cacabelos P, Noya M. Pentoxifylline: is it useful in multiple sclerosis?.  Reviews in Neurology. 2001;  32 529-531
  PubMedGoogle Scholar
• 64 Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.  Bio Drugs. 2002;  16 183-200
  PubMedGoogle Scholar
• 65 Bechthold D A, Kapoor R, Smith K J. Flecainide in experimental autoimmune encephalomyelitis.  Ann Neurol. 2004;  55 607-616
  CrossrefPubMedGoogle Scholar
• 66 Frank J A, Richert N, Lewis B, Bash C, Howard T, Civil R, Stone R, Eaton J, McFarland H, Leist T. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients.  Mult Scler. 2002;  8 24-29
  CrossrefPubMedGoogle Scholar
• 67 Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gp145 trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells.  Brain. 2000;  125 75-85
  PubMedGoogle Scholar
• 68 Linker R A, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R. et al . CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation.  Nat Med. 2000;  8 620-624
  PubMedGoogle Scholar
• 69 Brines M L, Ghezzi P, Keenan S, Agnello D, de Lanerolle N C, Cerami C. et al . Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.  Proc Natl Acad Sci USA. 2000;  9 10526-10531
  PubMedGoogle Scholar
• 70 Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M. et al . Erythropoietin therapy for acute stroke is both safe and beneficial.  Mol Med. 2002;  8 495-505
  PubMedGoogle Scholar
• 71 Navia B A, Jordan B, Price R W. The AIDS dementia complex I: Clinical features.  Ann Neurol. 1986;  19 517-535
  CrossrefPubMedGoogle Scholar
• 72 Price R W, Brew B, Sidtis J, Rosenblum M, Scheck A C, Cleary P. The brain in AIDS: Central nervous system HIV-1 infection and AIDS dementia complex.  Science. 1988;  239 586-592
  CrossrefPubMedGoogle Scholar
• 73 Sanchez-Ramon S, Canto-Nogues C, Munoz-Fernandez M A. Reconstructing the course of HIV1-associated progressive encephalopathy in children.  Med Sci Monit. 2002;  8 249-252
  PubMedGoogle Scholar
• 74 Tardieu M, Le Chenadec J, Persoz A, Meyer L, Blanche S, Mayaux M J. HIV-1-related encephalopathy in infants compared with children and adults. French Pediatric HIV Infection Study and the SEROCO Group.  Neurology. 2000;  54 1089-1095
  PubMedGoogle Scholar
• 75 Sacktor N, Lyles R H, Skolasky R, Kleeberger C, Selnes O A. et al . Multicenter AIDS Cohort Study. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990 - 1998.  Neurology. 2001;  56 257-260
  PubMedGoogle Scholar
• 76 Navia B A, Price R W. The acquired immunodeficiency syndrome dementia complex as the presenting sole manifestation of human immunodeficiency virus infection.  Arch Neurol. 1987;  44 65-69
  CrossrefPubMedGoogle Scholar
• 77 Rostásy K M, Monti L, Lipton S A, Hedreen J C, Gonzalez R G, Navia B A. HIV-leukoencephalopathy and TNF-α expression in neurons.  J Neurol Neurosurg Psychiatry. 2005;  76 960-964
  CrossrefPubMedGoogle Scholar
• 78 Cosenza M A, Zhao M L, Si Q, Lee S C. Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis.  Brain Pathol. 2002;  12 442-455
  PubMedGoogle Scholar
• 79 Gartner S. HIV infection and dementia.  Science. 2000;  287 602-604
  CrossrefPubMedGoogle Scholar
• 80 Wiley C, Achim C. Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome.  Ann Neurol. 1994;  36 673-676
  CrossrefPubMedGoogle Scholar
• 81 Smith T W, DeGirolami U, Henin D, Bolgert F, Hauw J J. Human immunodeficiency virus (HIV) leukoencephalopathy and the microcirculation.  J Neuropathol Exp Neurol. 1990;  49 357-370
  PubMedGoogle Scholar
• 82 Petito C K, Cash K S. Blood brain barrier abnormalities in the acquired immune deficiency syndrome: Immunohistochemical localization of serum proteins to postmortem brains.  Ann Neurol. 1992;  32 658-666
  CrossrefPubMedGoogle Scholar
• 83 Power C, Kong P A, Crawford T O, Wesselingh S, Glass J D, McArthur J C, Trapp B D. Cerebral white matter changes in acquired human immunodeficiency syndrome dementia: Alterations of the blood-brain barrier.  Ann Neurol. 1993;  34 339-350
  CrossrefPubMedGoogle Scholar
• 84 Petito C K, Roberts B. Evidence of apoptotic cell death in HIV encephalitis.  Am J Path. 1995;  146 1121-1130
  PubMedGoogle Scholar
• 85 Meyerhoff D J, MacKay S, Poole N, Dillon W P, Weiner M W, Fein G. N-Acetylaspartate reductions measured by 1 H MRSI in cognitively impaired HIV-seropositive individuals.  Magn Reson Imaging. 1994;  12 653-659
  PubMedGoogle Scholar
• 86 Tracey I, Carr C A, Guimaraes A R, Worth J L, Navia B A, Gonzalez R G. Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: A proton magnetic resonance spectroscopic study.  Neurology. 1996;  46 783-788
  PubMedGoogle Scholar
• 87 Zheng J, Ghorpade A, Niemann D, Cotter R L, Thylin M R, Epstein L. et al . Lymphotropic virions affect chemokine receptor-mediated neuronal signaling and apoptosis: implications for human immunodeficiency virus type 1-associated dementia.  J Virol. 1999;  73 8256-8267
  PubMedGoogle Scholar
• 88 Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton S A. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures.  Proc Natl Acad Sci USA. 1995;  92 7162-7166
  PubMedGoogle Scholar
• 89 Grilli M, Memo M. Nuclear factor-kB/Rel proteins. A point of convergence of signalling pathways relevant in neuronal function and dysfunction.  Biochem Pharmacol. 1999;  57 1-7
  CrossrefPubMedGoogle Scholar
• 90 New D R, Ma M, Epstein L G, Nath A, Gelbard H A. Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures.  J Neurovirol. 1997;  3 168-173
  PubMedGoogle Scholar
• 91 Shi B, Raina J, Lorenzo A, Busciglio J, Gabuzda D. Neuronal apoptosis induced by HIV-1 Tat protein and TNF-α: potentiation of neurotoxicity by oxidative stress and implications for HIV-1 dementia.  J Neurovirol. 1998;  4 281-290
  PubMedGoogle Scholar
• 92 Rostásy K M, Gorgun G, Kramer M, Melanson S M, Mathys J M, Yiannoutsos C. et al . TNF-α leads to increased cell surface expression of CXCR4 in SK-N-MC cells.  J Neurovirol. 2005;  11 1-9
  PubMedGoogle Scholar
• 93 Glass J D, Fedor H, Wesselingh S, McArthur J. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia.  Ann Neurol. 1995;  38 755-762
  CrossrefPubMedGoogle Scholar
• 94 Wesselingh S L, Takahashi K, Glass J D, McArthur J C. Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry.  J Neuroimmunology. 1997;  74 1-8
  PubMedGoogle Scholar
• 95 Conant K, McArthur J C, Griffin D E, Sjulson L, Wahl L M, Irani D N. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia.  Ann Neurol. 1999;  46 391-398
  CrossrefPubMedGoogle Scholar
• 96 Ferrando S, van Gorp W, McElhiney M. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function.  AIDS. 1998;  12 65-70
  CrossrefPubMedGoogle Scholar
• 97 Marra C M, Lockhart D, Zunt J R, Perrin M, Coombs R W, Collier A C. Changes in CSF and plasma HIV-RNA and cognition after starting potent antiretroviral therapy.  Neurology. 2003;  60 1388-1390
  PubMedGoogle Scholar
• 98 Navia B A, Dafni U, Simpson D, Tucker T, Singer E, McArthur J C. et al . A phase I/II trial with nimodipine for HIV-related neurological complications.  Neurology. 1998;  19 517-524
  PubMedGoogle Scholar
• 99 Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders . A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment.  Neurology. 1998;  50 645-651
  PubMedGoogle Scholar
• 100 Sacktor N, Schifitto G, McDermott M P, Marder K, McArthur J C, Kieburtz K. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.  Neurology. 2000;  54 233-235
  PubMedGoogle Scholar
• 101 Pulliam L, Irwin I, Kusdra L, Rempel H, Flitter W D, Garland W A. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation.  Brain Res. 2001;  893 95-103
  CrossrefPubMedGoogle Scholar
• 102 Clifford D B, McArthur J C, Schifitto G, Kieburtz K, McDermott M P, Letendre S, Cohen B A, Marder K, Ellis R J, Marra C M. Neurologic AIDS Research Consortium . A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment.  Neurology. 2002;  59 1568-1573
  PubMedGoogle Scholar
• 103 Lipton S A. Memantine prevents HIV coat protein-induced neuronal injury in-vitro.  Neurology. 1992;  42 1403-1405
  PubMedGoogle Scholar
• 104 Nath A, Haughey N J, Jones M, Anderson C, Bell J E, Geiger J D. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine.  Ann Neurol. 2000;  47 186-194
  CrossrefPubMedGoogle Scholar
• 105 Kaul M, Garden G A, Lipton S A. Pathways to neuronal injury and apoptosis in HIV-associated dementia.  Nature. 2001;  410 988-994
  CrossrefPubMedGoogle Scholar

Kevin Rostásy

Department of Pediatrics and Pediatric Neurology
Georg-August University Göttingen

Robert-Koch-Straße 40

37075 Göttingen

Germany

Email: Krostasy@excite.com